Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 7 de 7
Filter
2.
J Clin Gastroenterol ; 42(1): 18-22, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18097284

ABSTRACT

GOALS: To assess serologically diagnosed gastric body atrophy (GBA) by histology in a sample of the general population. BACKGROUND: GBA is a precursor lesion in gastric cancer. Data on GBA in a primary health care community in the Netherlands have not been reported. STUDY: Thirty-four subjects of 997 consecutive adults from a Dutch family practice had serologic GBA, according to hypergastrinemia (>100 ng/L), hypopepsinogenemia A (<17 microg/L), and a low pepsinogen A/C ratio (<1.6). Two years later, 25 subjects of this group, agreed in serologic retesting and gastroscopy with biopsies for histologic assessment according to the Sydney system. RESULTS: At serologic retesting, 20 of 25 subjects again fulfilled the serologic criteria of GBA. Histologic examination of the corpus biopsies showed advanced GBA in 18 subjects (75%) of 24 (1 subject had no corpus biopsies) and 17 of 19 (89%) subjects with repeated positive serology. After disclosure of serology results, reexamination of the biopsies revealed GBA also in the 2 patients with initially insufficient evidence of GBA, giving a concordance of 100% (19/19). One subject with normal serum gastrin at retesting had both antral and body atrophy giving a concordance between serologic and histologic GBA of 95% (19/20). No adenomatous polyps, tumors, or dysplastic alterations were found. CONCLUSIONS: Identification by serology of asymptomatic patients with advanced GBA in primary care is adequately possible and useful in selecting for endoscopy.


Subject(s)
Gastritis, Atrophic/diagnosis , Adult , Aged , Aged, 80 and over , Antibodies, Bacterial/blood , Atrophy/pathology , Autoantibodies/blood , Autoimmune Diseases/epidemiology , Biopsy , Chronic Disease , Cohort Studies , Diagnosis, Differential , Endoscopy , Female , Gastric Fundus/pathology , Gastrins/blood , Gastritis, Atrophic/blood , Helicobacter Infections/epidemiology , Helicobacter pylori/immunology , Humans , Male , Middle Aged , Netherlands/epidemiology , Pepsinogens/blood , Prevalence , Pyloric Antrum/pathology , Serologic Tests
3.
Eur J Gastroenterol Hepatol ; 18(8): 911-6, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16825911

ABSTRACT

BACKGROUND: Atrophic corpus gastritis predisposes to vitamin B12 deficiency and gastric cancer. Little is known about the seroprevalence of atrophic corpus gastritis in the general population of Western Europe. AIM: To investigate the seroprevalence of atrophic corpus gastritis in a West-European primary care community in relation to Helicobacter pylori infection and autoimmunity. METHODS: Nine hundred and ninety-seven consecutive persons attending one general practice were asked to participate in the study by completing a questionnaire and donating fasting blood. Gastrin, pepsinogen A and C, and antibodies to H. pylori and parietal cells were measured by well-validated immunological methods. Criteria for serological atrophic corpus gastritis were pepsinogen A < 17 microg/l, pepsinogen A/C ratio <1.6, and gastrin >100 ng/l. RESULTS: Thirty-four participants (3.4%) fulfilled the serological criteria of atrophic corpus gastritis. Twenty-one of them (62%) and 17 of 34 (50%) age-matched and sex-matched nested controls were H. pylori positive [NS; odds ratio, 1.62 (0.62-4.24)], while 15 of them (44%) and one of 34 controls had antibodies to parietal cells [P < 0.005; odds ratio, 24.0 (3.00-201)]. CONCLUSIONS: The seroprevalence of atrophic corpus gastritis in this primary care community is 3.4%. When compared with controls, the approximate relative risk of having atrophic corpus gastritis was significantly higher (P < 0.025) for antibodies to parietal cells (24.0) than to H. pylori (1.62). In view of the decreasing risk of H. pylori infection in the western world, it is likely that the impact of H. pylori on the development of atrophic corpus gastritis will further diminish.


Subject(s)
Antibodies, Bacterial/blood , Autoimmunity/physiology , Gastrins/blood , Gastritis, Atrophic/blood , Helicobacter pylori/immunology , Pepsinogens/blood , Adult , Aged , Aged, 80 and over , Case-Control Studies , Female , Gastritis, Atrophic/epidemiology , Humans , Male , Middle Aged , Netherlands , Parietal Cells, Gastric/immunology , Primary Health Care , Seroepidemiologic Studies
4.
Arterioscler Thromb Vasc Biol ; 26(1): 169-75, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16254203

ABSTRACT

OBJECTIVE: Interventions that promote liver-directed cholesterol flux can suppress atherosclerosis, as demonstrated for scavenger receptor-BI overexpression in hypercholesterolemic mice. In analogy, we speculate that increasing lipoprotein flux to the liver via the asialoglycoprotein receptor (ASGPr) may be of therapeutic value in hypercholesterolemia. METHODS AND RESULTS: A bifunctional glycolipid (LCO-Tyr-GalNAc3) with a high-nanomolar affinity for the ASGPr (inhibition constant 2.1+/-0.2 nmol/L) was synthesized that showed rapid association with lipoproteins on incubation with serum. Prior incubation of LCO-Tyr-GalNAc3 with radiolabeled low-density lipoprotein or high-density lipoprotein (0.5 microg/microg of protein) resulted in a dramatic induction of the liver uptake of these lipoproteins when injected intravenously into mice (70+/-3% and 78+/-1%, respectively, of the injected dose at 10 minutes of low-density lipoprotein and high-density lipoprotein), as mediated by the ASGPr on hepatocytes. Intravenously injected LCO-Tyr-GalNAc3 quantitatively incorporated into serum lipoproteins and evoked a strong and persistent (> or =48 hour) cholesterol-lowering effect in normolipidemic mice (37+/-2% at 6 hours) and hyperlipidemic apoE(-/-) mice (32+/-2% at 6 hours). The glycolipid was also effective on subcutaneous administration. CONCLUSIONS: LCO-Tyr-GalNAc3 is very effective in promoting cholesterol uptake by hepatocytes and, thus, may be a promising alternative for the treatment of those hyperlipidemic patients who do not respond sufficiently to conventional cholesterol-lowering therapies.


Subject(s)
Acetylgalactosamine/analogs & derivatives , Asialoglycoprotein Receptor/metabolism , Atherosclerosis/drug therapy , Cholesterol/metabolism , Glycolipids/pharmacology , Hyperlipidemias/drug therapy , Acetylgalactosamine/chemical synthesis , Animals , Apolipoproteins E/genetics , Atherosclerosis/metabolism , Glycolipids/chemical synthesis , Glycolipids/toxicity , Hyperlipidemias/metabolism , Lipoproteins, HDL/blood , Lipoproteins, HDL/pharmacokinetics , Lipoproteins, LDL/blood , Lipoproteins, LDL/pharmacokinetics , Liver/drug effects , Liver/metabolism , Macrophages/metabolism , Male , Mice , Mice, Inbred C57BL , Mice, Mutant Strains , Spleen/drug effects , Spleen/metabolism
5.
Hemoglobin ; 28(1): 1-5, 2004 Feb.
Article in English | MEDLINE | ID: mdl-15008259

ABSTRACT

Hb Evanston [alpha14(A12)Trp --> Arg] is considered to be a rare alpha chain mutant, and was originally observed in two Black families in 1982, inducing a mild Hb H disease phenotype in a homozygous state for the -alpha3.7 deletion ( -alpha(Evanston)/ -alpha). The mutant, evidently linked with one of the two -alpha3.7 thalassemia (thal) alleles, was considered to be unstable and rapidly proteolyzed. We describe Hb Evanston in three new independent Asian cases, all induced by a TGG --> CGG transition. In all cases the mutation is linked to the alpha1-globin gene, either on a wild type allele or in linkage with the common -alpha3.7 and -alpha4.2 deletion alleles. The beta/alpha ratio was balanced in the presence of the mutation only, and accordingly unbalanced in co-inheritance with the deletion defects. Although a second independent mutation event on a -alpha3.7 or a -alpha4.2 deletion allele could not be excluded, we conclude that at least one independent Hb Evanston mutation has occurred on a wild type allele in the Asian populations. Unstable Hb tetramers tend to degrade and disappear during purification. Both Hb Evanston tetramers, formed in combination with normal beta and delta chains, remain perfectly stable after extensive purification and concentration steps, suggesting an early posttranslational thalassemic effect, probably at the dimer/tetramer affinity level.


Subject(s)
Hemoglobins, Abnormal/genetics , alpha-Thalassemia/genetics , Adult , Afghanistan , Alleles , Amino Acid Substitution , Child, Preschool , Female , Genetic Variation , Genotype , Humans , Middle Aged , Pedigree , Sequence Deletion
6.
J Infect Dis ; 189(5): 892-900, 2004 Mar 01.
Article in English | MEDLINE | ID: mdl-14976607

ABSTRACT

BACKGROUND: Several studies have shown an inverse association between helminth infections and atopy, but none have clearly established that the pathogens themselves, rather than other associated factors, cause the suppression of atopy. To show a direct link, prospective intervention studies are required. METHODS: A randomized, controlled trial was performed to study whether repeated anthelminthic treatment results in increased allergic sensitivity to house dust mites (HDMs) in chronically infected children. The trial population consisted of 317 Gabonese schoolchildren with a high prevalence of intestinal helminths. Intervention consisted of treatment every 3 months with praziquantel and mebendazole and with placebo in the control group. Follow-up lasted 30 months: at 6-month intervals, skin-test sensitivity to mites, helminth infection status, and levels of total IgE were determined. RESULTS: Treatment resulted in a significant increase in the rate of developing skin sensitivity to HDMs (hazard ratio, 2.51; 95% confidence interval, 1.85-3.41), which was mediated, in part, by reductions in Ascaris and/or Trichuris infections. Levels of total IgE were reduced, but this did not mediate the effect of treatment on skin-test reactivity. CONCLUSIONS: Anthelminthic treatment of chronically infected children results in increased atopic reactivity, which indicates that helminths directly suppress allergic reactions.


Subject(s)
Anthelmintics/therapeutic use , Drug Hypersensitivity/epidemiology , Helminthiasis/drug therapy , Intestinal Diseases, Parasitic/drug therapy , Mites/immunology , Adolescent , Animals , Anthelmintics/adverse effects , Ascariasis/drug therapy , Ascariasis/epidemiology , Child , Child, Preschool , Follow-Up Studies , Gabon/epidemiology , Helminthiasis/epidemiology , Humans , Insect Vectors , Intestinal Diseases, Parasitic/epidemiology , Prevalence , Proportional Hazards Models , Regression Analysis , Research Design , Skin Tests , Time Factors , Trichuriasis/drug therapy , Trichuriasis/epidemiology
7.
Br J Haematol ; 118(3): 843-6, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12181057

ABSTRACT

The effect of caeruloplasmin levels on the sensitivity for activated protein C (APC), measured by a clotting assay based on the activated partial thromboplastin time, was investigated in a large group of healthy individuals without factor V Leiden. A modest inverse association between caeruloplasmin and normalized APC sensitivity ratio was found (regression coefficient beta = -0.33 x 10-2; 95% confidence interval, -0.42 x 10-2 to -0.24 x 10-2). After adjustment for sex and oral contraceptive use, this association weakened (beta = -0.19 x 10-2; 95% CI: -0.34 x 10-2 to -0.05 x 10-2). After additional adjustment for factor VIII levels, which are known to influence the assay, the effect of caeruloplasmin on APC sensitivity completely disappeared.


Subject(s)
Activated Protein C Resistance/blood , Ceruloplasmin/analysis , Adolescent , Adult , Aged , Case-Control Studies , Contraceptives, Oral, Hormonal/pharmacology , Factor VIII/analysis , Female , Humans , Male , Middle Aged , Partial Thromboplastin Time , Postmenopause/blood , Premenopause/blood , Protein C/metabolism , Reference Values
SELECTION OF CITATIONS
SEARCH DETAIL
...